Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted 20,000 restricted stock units (RSUs) to a new non-executive employee. The RSUs were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.
Fate Therapeutics (NASDAQ: FATE), una compagnia biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC, ha assegnato 20.000 unità di azioni vincolate (RSU) a un nuovo dipendente non esecutivo. Le RSU sono state approvate dal Comitato Compensi e concesse nell'ambito del Piano di Induzione Equity Ampliato e Riconfigurato dell'Azienda, rispettando la Regola di Quotazione 5635(c)(4) di Nasdaq. Le RSU matureranno nel corso di quattro anni, con il 25% che matura annualmente, a condizione di un impiego continuativo.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en fase clínica centrada en inmunoterapias celulares derivadas de iPSC, ha otorgado 20,000 unidades de acciones restringidas (RSUs) a un nuevo empleado no ejecutivo. Las RSUs fueron aprobadas por el Comité de Compensación y concedidas bajo el Plan de Inducción Ampliado y Reestructurado de la Compañía, cumpliendo con la Regla de Cotización 5635(c)(4) de Nasdaq. Las RSUs se harán efectivas en un período de cuatro años, con un 25% que se hará efectivo anualmente, condicionado a la continuidad del empleo.
Fate Therapeutics (NASDAQ: FATE)는 iPSC 유래 세포 면역 요법에 중점을 둔 임상 단계의 생명공학 회사로, 새로운 비상무 직원에게 20,000개의 제한 주식 유닛(RSU)를 부여했습니다. RSU는 보상위원회에 의해 승인되었으며, 회사의 수정 및 재구성된 유인 주식 계획에 따라 부여되었으며, 나스닥 상장 규정 5635(c)(4)를 준수합니다. RSU는 4년 동안 발생하며, 매년 25%씩 발생할 예정이며, 지속적인 고용에 따라 달라집니다.
Fate Therapeutics (NASDAQ: FATE), une entreprise biopharmaceutique en phase clinique axée sur les immunothérapies cellulaires dérivées de iPSC, a accordé 20 000 unités d'actions restreintes (RSU) à un nouvel employé non-exécutif. Les RSU ont été approuvées par le Comité de Rémunération et accordées dans le cadre du Plan D’incitation en Actions Aménagé et Réactualisé de la Société, conformément à la Règle de Cotation 5635(c)(4) de Nasdaq. Les RSU matureront sur une période de quatre ans, avec 25% qui maturent chaque année, sous réserve d'un emploi continu.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien spezialisiert hat, hat 20.000 eingeschränkte Aktieneinheiten (RSUs) an einen neuen nicht-executive Mitarbeiter vergeben. Die RSUs wurden vom Vergütungsausschuss genehmigt und im Rahmen des geänderten und neu gefassten Anreizaktienplans des Unternehmens vergeben, der die Nasdaq-Listing-Regel 5635(c)(4) einhält. Die RSUs werden über einen Zeitraum von vier Jahren fällig, wobei 25% jährlich fällig werden, abhängig von einer fortlaufenden Anstellung.
- None.
- None.
SAN DIEGO, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on November 1, 2024 the Company granted restricted stock units (RSUs) representing 20,000 shares of its common stock to one newly-hired non-executive employee. The grant was approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many RSUs did Fate Therapeutics (FATE) grant to its new employee in November 2024?
What is the vesting schedule for Fate Therapeutics' (FATE) November 2024 RSU grant?
Under which rule did Fate Therapeutics (FATE) grant the November 2024 RSUs?
